| Title |
Impact of medication therapy management in patients with Parkinson’s disease
|
|---|---|
| Published in |
International Journal of Clinical Pharmacy, November 2015
|
| DOI | 10.1007/s11096-015-0206-0 |
| Pubmed ID | |
| Authors |
Martina Henrichsmann, Georg Hempel |
| Abstract |
Background Since the new German Apothekenbetriebsordnung was released, medication therapy management (MTM) has increased in importance. MTM is intended to improve the quality of life of patients. Objectives The aim of this study was to improve the quality of life of patients with Parkinson's disease through an MTM by a community pharmacist. Setting The patients were recruited in cooperation with the Deutsche Parkinson Vereinigung e.V. (dPV) in Germany. Methods All patients were evaluated at baseline (t0) and after a follow-up of 4 months (t1). During the intervention period, the pharmacists implemented an MTM with standardized pharmaceutical care. Main outcome measure The effects of the interventions were measured by the Unified Parkinson Disease Rating Scale (UPDRS) and the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS). Results In this study, 90 patients with Parkinson's disease were included. The most common intervention was to find a therapy for untreated comorbidities. The UPDRS or MDS-UPDRS improved significantly after the intervention period by a median change rate of 1 (p < 0.05) or rather 2 (p < 0.05) compared to the baseline. Conclusion The study shows that the quality of life in Parkinson's disease patients improved significantly through MTM. |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 78 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 23% |
| Student > Bachelor | 8 | 10% |
| Student > Ph. D. Student | 8 | 10% |
| Other | 7 | 9% |
| Researcher | 6 | 8% |
| Other | 11 | 14% |
| Unknown | 20 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 26% |
| Medicine and Dentistry | 16 | 21% |
| Nursing and Health Professions | 5 | 6% |
| Agricultural and Biological Sciences | 4 | 5% |
| Psychology | 3 | 4% |
| Other | 7 | 9% |
| Unknown | 23 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2017.
All research outputs
#5,804,141
of 23,001,641 outputs
Outputs from International Journal of Clinical Pharmacy
#280
of 1,101 outputs
Outputs of similar age
#89,016
of 387,500 outputs
Outputs of similar age from International Journal of Clinical Pharmacy
#4
of 19 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,101 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,500 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.